

## **SUMMARY OF PRODUCT CHARACTERISTICS**

## **1. NAME OF THE MEDICINAL PRODUCT**

Ziomycin 250 mg /500 mg Tablets

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Ziomycin 250:

Each film coated tablet contains:

Azithromycin dihydrate USP equivalent to Azithromycin USP ... 250 mg

Ziomycin 500:

Each film coated tablet contains:

Azithromycin dihydrate USP equivalent to Azithromycin USP ... 500 mg

For excipients, see 6.1

## **3. PHARMACEUTICAL FORM**

Film Coated tablets 250 mg /500 mg

Ziomycin 250:

Yellow coloured, film coated capsule shaped tablets with engraving "A 250" on one side and plain on other side.

Ziomycin 500:

Yellow coloured, film coated capsule shaped tablets with engraving "A 500" on one side and plain on other side.

## **4. CLINICAL PARTICULARS**

### **4.1 Therapeutic indications**

Ziomycin tablet is indicated for the treatment of the following infections when known or likely to be due to one or more susceptible microorganisms (see section 5.1):

- bronchitis
- community-acquired pneumonia
- sinusitis
- pharyngitis/tonsillitis (see section 4.4 regarding streptococcal infections)
- otitis media
- skin and soft tissue infections
- uncomplicated genital infections due to Chlamydia trachomatis and Neisseria gonorrhoeae.

Considerations should be given to official guidance regarding the appropriate use of antibacterial agents.

### **4.2 Posology and method of administration**

Posology:

Ziomycin tablets should be given as a single daily dose.

In common with many other antibiotics Ziomycin tablets should be taken at least 1 hour before or 2 hours after food.

**Children over 45 kg body weight and adults, including elderly patients:**

The total dose of azithromycin is 1500 mg which should be given over three days (500 mg once daily).

In uncomplicated genital infections due to *Chlamydia trachomatis*, the dose is 1000 mg as a single oral dose. For susceptible *Neisseria gonorrhoeae* the recommended dose is 1000 mg or 2000 mg of azithromycin in combination with 250 mg or 500 mg ceftriaxone according to local clinical treatment guidelines. For patients who are allergic to penicillin and/or cephalosporins, prescribers should consult local treatment guidelines.

**Paediatric population:**

**In children under 45 kg body weight:** Ziomycin tablets are not suitable for children under 45 kg.

**Renal impairment:**

No dose adjustment is necessary in patients with mild to moderate renal impairment (GFR 10 - 80 ml/min). Caution should be exercised when azithromycin is administered to patients with severe renal impairment (GFR < 10 ml/min) (see section 4.4 and section 5.2).

**Hepatic impairment:**

Since azithromycin is metabolised in the liver and excreted in the bile, the drug should not be given to patients suffering from severe liver disease. No studies have been conducted regarding treatment of such patients with azithromycin (see section 4.4).

Method of administration:

Ziomycin tablets are for oral administration only.

**4.3 Contraindications**

Ziomycin is contra-indicated in patients with a known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or to any of the excipients (listed in section 6.1).

**4.4 Special warnings and precautions for use**

*Hypersensitivity*

As with erythromycin and other macrolides, rare serious allergic reactions including angioneurotic oedema and anaphylaxis (rarely fatal), have been reported. Some of these reactions with azithromycin have resulted in recurrent symptoms and required a longer period of observation and treatment.

*Hepatotoxicity*

Since the liver is the principal route of elimination for azithromycin, the use of azithromycin should be undertaken with caution in patients with significant hepatic disease. Cases of fulminant hepatitis potentially leading to life-threatening liver failure have been reported with azithromycin (see Undesirable effects). Some patients may have had pre-existing hepatic disease or may have been taking other hepatotoxic medicinal products.

In case of signs and symptoms of liver dysfunction, such as rapid developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy, liver function tests/ investigations should be performed immediately. Azithromycin administration should be stopped if liver dysfunction has emerged.

*Ergot derivatives*

In patients receiving ergot derivatives, ergotism has been precipitated by co-administration of some macrolide antibiotics. There are no data concerning the possibility of an interaction between ergot and

azithromycin. However, because of the theoretical possibility of ergotism, azithromycin and ergot derivatives should not be co-administrated.

#### *Prolongation of the QT interval*

Prolonged cardiac repolarisation and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen in treatment with other macrolides. A similar effect with azithromycin cannot be completely ruled out in patients at increased risk for prolonged cardiac repolarisation (see Undesirable effects); therefore caution is required when treating patients:

- With congenital or documented QT prolongation
- Currently receiving treatment with other active substance known to prolong QT interval such as antiarrhythmics of classes Ia and III, cisapride and terfenadine
- With electrolyte disturbance, particularly in case of hypokalaemia and hypomagnesaemia
- With clinically relevant bradycardia, cardiac arrhythmia or severe cardiac insufficiency.

#### *Superinfection*

As with any antibiotic preparation, observation for signs of superinfection with non-susceptible organisms including fungi is recommended.

#### *Clostridium difficile associated diarrhoea*

*Clostridium difficile* associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents, including azithromycin, and may range in severity from mild diarrhoea to fatal colitis. Strains of *C. difficile* producing hypertoxin A and B contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. Therefore, CDAD must be considered in patients who present with diarrhoea during or subsequent to the administration of any antibiotics. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. Discontinuation of therapy with azithromycin and the administration of specific treatment for *C. difficile* should be considered.

#### *Streptococcal infections*

Penicillin is usually the first choice for treatment of pharyngitis/tonsillitis due to *Streptococcus pyogenes* and also for prophylaxis of acute rheumatic fever. Azithromycin is in general effective against streptococcus in the oropharynx, but no data are available that demonstrate the efficacy of azithromycin in preventing acute rheumatic fever.

#### *Renal impairment:*

In patients with severe renal impairment (GFR <10 ml/min) a 33% increase in systemic exposure to azithromycin was observed (see Pharmacokinetic properties).

#### *Myasthenia gravis*

Exacerbations of the symptoms of myasthenia gravis and new onset of myasthenia syndrome have been reported in patients receiving azithromycin therapy (see Undesirable effects).

#### *Diabetes*

Azithromycin tablets are for oral administration only.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

### **4.5 Interaction with other medicinal products and other types of interaction**

**Antacids:** In a pharmacokinetic study investigating the effects of simultaneous administration of antacid with azithromycin, no effect on overall bioavailability was seen, although peak serum concentrations were reduced by approximately 24%. In patients receiving both azithromycin and antacids, the drugs should not be taken simultaneously.

**Cetirizine:** In healthy volunteers, co-administration of a 5-day regimen of azithromycin with 20 mg cetirizine at steady-state resulted in no pharmacokinetic interaction and no significant changes in the QT interval.

**Didanosine (*Dideoxyinosine*):** Co-administration of 1200 mg/day azithromycin with 400 mg/day didanosine in six HIV-positive subjects did not appear to affect the steady-state pharmacokinetics of didanosine as compared to placebo.

**Digoxin and colchicine:** concomitant administration of macrolide antibiotics, including azithromycin, with P-glycoprotein substrates such as digoxin and colchicine, has been reported to result in increased serum levels of the P-glycoprotein substrate. Therefore, if azithromycin and P-glycoprotein substrates such as digoxin are administered concomitantly, the possibility of elevated serum digoxin concentrations should be considered. Clinical monitoring, and possibly serum digoxin levels, during treatment with azithromycin and after its discontinuation are necessary.

**Zidovudine:** Single 1000 mg doses and multiple 1200 mg or 600 mg doses of azithromycin had little effect on the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolite. However, administration of azithromycin increased the concentrations of phosphorylated zidovudine, the clinically active metabolite, in peripheral blood mononuclear cells. The clinical significance of this finding is unclear, but it may be of benefit to patients.

Azithromycin does not interact significantly with the hepatic cytochrome P450 system. It is not believed to undergo the pharmacokinetic drug interactions as seen with erythromycin and other macrolides. Hepatic cytochrome P450 induction or inactivation via cytochrome-metabolite complex does not occur with azithromycin.

**Ergot derivatives:** Due to the theoretical possibility of ergotism, the concurrent use of azithromycin with ergot derivatives is not recommended (see section 4.4).

Pharmacokinetic studies have been conducted between azithromycin and the following drugs known to undergo significant cytochrome P450 mediated metabolism.

**Atorvastatin:** Co-administration of atorvastatin (10 mg daily) and azithromycin (500 mg daily) did not alter the plasma concentrations of atorvastatin (based on a HMG CoA-reductase inhibition assay).

**Carbamazepine:** In a pharmacokinetic interaction study in healthy volunteers, no significant effect was observed on the plasma levels of carbamazepine or its active metabolite in patients receiving concomitant azithromycin.

**Cimetidine:** In a pharmacokinetic study investigating the effects of a single dose of cimetidine, given 2 hours before azithromycin, on the pharmacokinetics of azithromycin, no alteration of azithromycin pharmacokinetics was seen.

**Coumarin-type oral anticoagulants:** In a pharmacokinetic interaction study, azithromycin did not alter the anticoagulant effect of a single dose of 15 mg warfarin administered to healthy volunteers. There have been reports received in the post-marketing period of potentiated anticoagulation subsequent to co-administration of azithromycin and coumarin-type oral anticoagulants. Although a causal relationship has not been established, consideration should be given to the frequency of monitoring prothrombin time when azithromycin is used in patients receiving coumarin-type oral anticoagulants.

**Ciclosporin:** In a pharmacokinetic study with healthy volunteers who were administered a 500 mg/day oral dose of azithromycin for 3 days and were then administered a single 10 mg/kg oral dose of ciclosporin, the resulting ciclosporin  $C_{max}$  and  $AUC_{0-5}$  were found to be significantly elevated (by 24% and 21% respectively), however no significant changes were seen in  $AUC_{0-\infty}$ . Consequently, caution should be exercised before considering concurrent administration of these drugs. If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.

**Efavirenz:** Co-administration of a single dose of 600 mg azithromycin and 400 mg efavirenz daily for 7 days did not result in any clinically significant pharmacokinetic interactions.

**Fluconazole:** Co-administration of a single dose of 1200 mg azithromycin did not alter the pharmacokinetics of a single dose of 800 mg fluconazole. Total exposure and half-life of azithromycin were unchanged by the co-administration of fluconazole, however, a clinically insignificant decrease in  $C_{max}$  (18%) of azithromycin was observed.

**Indinavir:** Co-administration of a single dose of 1200 mg azithromycin had no statistically significant effect on the pharmacokinetics of indinavir administered as 800 mg three times daily for 5 days.

**Methylprednisolone:** In a pharmacokinetic interaction study in healthy volunteers, azithromycin had no significant effect on the pharmacokinetics of methylprednisolone.

**Midazolam:** In healthy volunteers, co-administration of 500mg/day azithromycin for 3 days did not cause clinically significant changes in the pharmacokinetics and pharmacodynamics of a single dose of 15mg midazolam.

**Nelfinavir:** Co-administration of azithromycin (1200 mg) and nelfinavir at steady state (750 mg three times daily) resulted in increased azithromycin concentrations. No clinically significant adverse effects were observed and no dose adjustment was required.

**Rifabutin:** Co-administration of azithromycin and rifabutin did not affect the serum concentrations of either drug. Neutropenia was observed in subjects receiving concomitant treatment of azithromycin and rifabutin. Although neutropenia has been associated with the use of rifabutin, a causal relationship to combination with azithromycin has not been established (see section 4.8.).

**Sildenafil:** In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC and  $C_{max}$ , of sildenafil or its major circulating metabolite.

**Terfenadine:** Pharmacokinetic studies have reported no evidence of an interaction between azithromycin and terfenadine. There have been rare cases reported where the possibility of such an interaction could not be entirely excluded; however there was no specific evidence that such an interaction had occurred.

**Theophylline:** There is no evidence of a clinically significant pharmacokinetic interaction when azithromycin and theophylline are co-administered to healthy volunteers.

**Triazolam:** In 14 healthy volunteers, co-administration of 500mg azithromycin on Day 1 and 250 mg on Day 2 with 0.125 mg triazolam on Day 2 had no significant effect on any of the pharmacokinetic variables for triazolam compared to triazolam and placebo.

**Trimethoprim/sulfamethoxazole:** Co-administration of trimethoprim/sulfamethoxazole DS (160 mg/800 mg) for 7 days with 1200mg azithromycin on Day 7 had no significant effect on peak concentrations, total exposure or urinary excretion of either trimethoprim or sulfamethoxazole. Azithromycin serum concentrations were similar to those seen in other studies.

## 4.6 Fertility, Pregnancy and lactation

### Pregnancy

Animal reproduction studies have been performed at doses up to moderately maternally toxic dose concentrations. In these studies, no evidence of harm to the foetus due to azithromycin was found. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, azithromycin should be used during pregnancy only if clearly needed.

### Breast-feeding

There are no data on secretion in breast milk. As many drugs are excreted in human milk, azithromycin should not be used in the treatment of a lactating woman unless the physician feels that the potential benefits justify the potential risks to the infant.

## 4.7 Effects on ability to drive and use machines

There is no evidence to suggest that azithromycin tablets may have an effect on a patient's ability to

drive or operate machinery.

#### **4.8 Undesirable effects**

Azithromycin is well tolerated with a low incidence of side effects.

The section below lists the adverse reactions identified through clinical trial experience and postmarketing surveillance by system organ class and frequency. Adverse reactions identified from post-marketing experience are included in italics. The frequency grouping is defined using the following convention: Very common ( $\geq 1/10$ ); Common ( $\geq 1/100$  to  $< 1/10$ ); Uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); Rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); Very Rare ( $< 1/10,000$ ); and Not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

#### **Adverse reactions possibly or probably related to azithromycin based on clinical trial experience and post-marketing surveillance:**

##### **Infections and Infestations**

*Uncommon:* Candidiasis, oral candidiasis, vaginal infection

*Not known:* *Pseudomembranous colitis* (see special warnings and precautions for use)

##### **Blood and Lymphatic System Disorders**

*Uncommon:* Leukopenia, neutropenia

*Not known:* *Thrombocytopenia, haemolytic anaemia*

##### **Immune System Disorders**

*Uncommon:* Angioedema, hypersensitivity

*Not known:* *Anaphylactic reaction* (see section 4.4)

##### **Metabolism and Nutrition Disorders**

*Common:* Anorexia

##### **Psychiatric Disorders**

*Uncommon:* Nervousness

*Rare:* Agitation

*Not known:* *Aggression, anxiety*

##### **Nervous System Disorders**

*Common:* Dizziness, headache, paraesthesia, dysgeusia

*Uncommon:* Hypoaesthesia, somnolence, insomnia

*Not known:* *Syncope, convulsion, psychomotor hyperactivity, anosmia, ageusia, parosmia, Myasthenia gravis* (see special warnings and precautions for use).

##### **Eye Disorders**

*Common:* Visual impairment

##### **Ear and Labyrinth Disorders**

*Common:* Deafness

*Uncommon:* Hearing impaired, tinnitus

*Rare:* Vertigo

##### **Cardiac Disorders**

**Uncommon:** Palpitations

**Not known:** *Torsades de pointes* (see special warnings and precautions for use), *arrhythmia* (see special warnings and precautions for use) including *ventricular tachycardia*

### **Vascular Disorders**

**Not known:** *Hypotension*

### **Gastrointestinal Disorders**

**Very common:** Diarrhoea, abdominal pain, nausea, flatulence

**Common:** Vomiting, dyspepsia

**Uncommon:** Gastritis, constipation

**Not known:** *Pancreatitis, tongue discolouration*

### **Hepatobiliary Disorders**

**Uncommon:** Hepatitis

**Rare:** Hepatic function abnormal

**Not known:** *Hepatic failure* (See section 4.4), which has rarely resulted in death, *hepatitis fulminant, hepatic necrosis, jaundice cholestatic*

### **Skin and Subcutaneous Tissue Disorders**

**Common:** Pruritus and rash

**Uncommon:** Stevens-Johnson syndrome, photosensitivity reaction, urticaria.

**Rare:** Acute Generalized Exanthematous Pustulosis (AGEP)\*§

Drug reaction with eosinophilia and systemic symptoms (DRESS)\*§

**Not known:** *Toxic epidermal necrolysis, erythema multiforme*

### **Musculoskeletal, Connective Tissue Disorders**

**Common:** Arthralgia

### **Renal and Urinary Disorders**

**Not known:** *Renal failure acute, nephritis interstitial*

### **General disorders and Administration Site Conditions**

**Common:** Fatigue

**Uncommon:** Chest pain, oedema, malaise, asthenia

### **Investigations**

**Common:** Lymphocyte count decreased, eosinophil count increased, blood bicarbonate decreased

**Uncommon:** Aspartate aminotransferase increased, alanine aminotransferase increased, blood bilirubin increased, blood urea increased, blood creatinine increased, blood potassium abnormal

**Not known:** *Electrocardiogram QT prolonged* (see special warnings and precautions for use)

\*ADR identified post-marketing

§ADR frequency represented by the estimated upper limit of the 95% confidence interval calculated using the “Rule of 3”.

### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via EFDA yellow Card Scheme, online at <https://primaryreporting.who-umc.org/ET> or toll free call 8482 to Ethiopian food and drug authority



(EFDA).

#### 4.9 Overdose

Adverse events experienced in higher than recommended doses were similar to those seen at normal doses. The typical symptoms of an overdose with macrolide antibiotics include reversible loss of hearing, severe nausea, vomiting and diarrhoea. In the event of overdose, the administration of medicinal charcoal and general symptomatic treatment and supportive measures are indicated as required.

### 5. PHARMACOLOGICAL PROPERTIES

#### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antibacterials for systemic use. Macrolides, ATC code: J01FA10

##### Mechanism of action:

Azithromycin is a macrolide antibiotic belonging to the azalide group. The molecule is constructed by adding a nitrogen atom to the lactone ring of erythromycin A. The chemical name of azithromycin is 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A. The molecular weight is 749.0. The mechanism of action of azithromycin is based upon the suppression of bacterial protein synthesis by means of binding to the ribosomal 50s sub-unit and inhibition of peptide translocation.

##### Mechanism of resistance:

Resistance to azithromycin may be inherent or acquired. There are three main mechanisms of resistance in bacteria: target site alteration, alteration in antibiotic transport and modification of the antibiotic.

Azithromycin demonstrates cross resistance with erythromycin resistant gram positive isolates. A decrease in macrolide susceptibility over time has been noted particularly in *Streptococcus pneumoniae* and *Staphylococcus aureus*. Similarly, decreased susceptibility has been observed among *Streptococcus viridans* and *Streptococcus agalactiae* (Group B) streptococcus against other macrolides and lincosamides.

##### **Breakpoints**

Azithromycin susceptibility breakpoints for typical bacterial pathogens, as published by EUCAST are:

Organism	MIC breakpoints (mg/L)	
	Susceptible (S≤)	Resistant (R>)
<i>Staphylococcus</i> spp.	1	2
<i>Streptococcus</i> groups A, B, C and G	0.25	0.5
<i>Streptococcus pneumoniae</i>	0.25	0.5
<i>Haemophilus influenzae</i>	0.12	4
<i>Moraxella catarrhalis</i>	0.25	0.5
<i>Neisseria gonorrhoeae</i>	0.25	0.5

##### **Susceptibility**

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

Table: Antibacterial spectrum of Azithromycin

<b>Commonly susceptible species</b>
<b>Aerobic Gram-positive microorganisms</b>
<i>Staphylococcus aureus</i> Methycillin-susceptible
<i>Streptococcus pneumoniae</i> Penicillin-susceptible
<i>Streptococcus pyogenes</i> (Group A)
<b>Aerobic Gram-negative microorganisms</b>
<i>Haemophilus influenzae</i> <i>Haemophilus parainfluenzae</i>
<i>Legionella pneumophila</i>
<i>Moraxella catarrhalis</i>
<i>Neisseria gonorrhoeae</i>
<i>Pasteurella multocida</i>
<b>Anaerobic microorganisms</b>
<i>Clostridium perfringens</i>
<i>Fusobacterium spp.</i>
<i>Prevotella spp.</i>
<i>Porphyromonas spp.</i>
<b>Other microorganisms</b>
<i>Chlamydia trachomatis</i>
<b>Species for which acquired resistance may be a problem</b>
<b>Aerobic Gram-positive microorganisms</b>
<i>Streptococcus pneumoniae</i> Penicillin-intermediate Penicillin-resistant
<b>Inherently resistant organisms</b>
<b>Aerobic Gram-positive microorganisms</b>
<i>Enterococcus faecalis</i> Staphylococci MRSA, MRSE*
<b>Anaerobic microorganisms</b>
Bacteroides fragilis group

\* Methycillin-resistant staphylococci have a very high prevalence of acquired resistance to macrolides and have been placed here because they are rarely susceptible to azithromycin.

## 5.2 Pharmacokinetic properties

### Absorption

Bioavailability after oral administration is approximately 37%. Peak plasma concentrations are attained 2-3 hours after taking the medicinal product.

### Distribution

Orally administered azithromycin is widely distributed throughout the body. In pharmacokinetic studies it has been demonstrated that the concentrations of azithromycin measured in tissues are noticeably higher (as much as 50 times) than those measured in plasma, which indicates that the agent strongly binds to tissues.

Binding to serum proteins varies according to plasma concentration and ranges from 12% at 0.5 microgram/ml up to 52% at 0.05 microgram azithromycin/ml serum. The mean volume of distribution at steady state (V<sub>Vss</sub>) has been calculated to be 31.1 l/kg.

#### Elimination

The terminal plasma elimination half-life closely reflects the elimination half-life from tissues of 2-4 days.

Approximately 12% of an intravenously administered dose of azithromycin is excreted unchanged in urine within the following three days. Particularly high concentrations of unchanged azithromycin have been found in human bile. Also in bile, ten metabolites were detected, which were formed through N- and O- demethylation, hydroxylation of desosamine – and aglycone rings and cleavage of cladinose conjugate. Comparison of the results of liquid chromatography and microbiological analyses has shown that the metabolites of azithromycin are not microbiologically active.

In animal tests, high concentrations of azithromycin have been found in phagocytes. It has also been established that during active phagocytosis higher concentrations of azithromycin are released from inactive phagocytes. In animal models this results in high concentrations of azithromycin being delivered to the site of infection.

### **5.3 Preclinical safety data**

Phospholipidosis (intracellular phospholipid accumulation) has been observed in several tissues (e.g. eye, dorsal root ganglia, liver, gallbladder, kidney, spleen, and/or pancreas) of mice, rats, and dogs given multiple doses of azithromycin. Phospholipidosis has been observed to a similar extent in the tissues of neonatal rats and dogs. The effect has been shown to be reversible after cessation of azithromycin treatment. The significance of the finding for animals and for humans is unknown.

#### Carcinogenic potential:

Long-term studies in animals have not been performed to evaluate carcinogenic potential as the drug is indicated for short-term treatment only and there were no signs indicative of carcinogenic activity.

#### Mutagenic potential:

There was no evidence of a potential for genetic and chromosome mutations in in-vivo and in-vitro test models.

#### Reproductive toxicity:

In animal studies for embryotoxic effects of the substance, no teratogenic effect was observed in mice and rats. In rats, azithromycin doses of 100 and 200 mg/kg bodyweight/day led to mild retardation of fetal ossification and in maternal weight gain. In peri- and postnatal studies in rats, mild retardation following treatment with 50 mg/kg/day azithromycin and above was observed.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Microcrystalline cellulose PH101, Croscarmellose sodium, Sodium lauryl sulfate, Povidone K-90, Purified talc, Magnesium stearate, HPMC 2910/Hypromellose, Titanium dioxide, Macrogol and Iron oxide yellow.

### **6.2 Incompatibilities**

Not available.

### **6.3 Shelf Life:**

3 years.

### **6.4 Special precautions for storage**

Store below 30 °C.

Keep all medicines out of reach of children.

### **6.5 Nature and content of container**

**250 mg:** 6 tablets are packed in aluminium PVC/PVDC blister, such 1 or 20 blister(s) are packed in a carton along with pack insert.

**500 mg:** 3 tablets are packed in aluminium PVC/PVDC blister, such 1 or 20 blister(s) are packed in a carton along with pack insert.

## **7. MARKETING AUTHORIZATION HOLDER**

Kusum Healthcare Pvt. Ltd.,  
SP 289 (A), RIICO Industrial area,  
Chopanki, Bhiwadi (Rajasthan), India

## **8. MARKETING AUTHORIZATION NUMBER**

250 mg: 04572/07093/NMR/2018

## **9. DATE OF FIRST AUTHORIZATION/ RENEWAL OF AUTHORIZATION**

18 July 2019

## **10. DATE OF REVISION OF THE TEXT**

08/2023

## **11. REFERENCES**

SmPC published on electronic medicines compendium

<https://www.medicines.org.uk/emc#gref>

The MHRA published product information

<https://products.mhra.gov.uk/>

Human medicine European public assessment report

<https://www.ema.europa.eu/en/medicines>